Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Next Previous
Search
Trial Profile

Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Yersinia pestis vaccine (Primary) ; CpG 1018
  • Indications Plague; Pneumonic plague
  • Focus Pharmacodynamics
  • Sponsors Dynavax Technologies

Most Recent Events

  • 13 Jan 2025 According to a Dynavax Europe media release, Dynavax and the DoD executed a new agreement for approximately $30 million through the first half of 2027 to support additional Phase 2 clinical and manufacturing activities
  • 06 Aug 2024 According to a Dynavax Europe media release, company anticipates providing a program update, based on results from this study and pre-clinical study.
  • 06 Aug 2024 According to a Dynavax Europe media release, this trial is being conducted in collaboration and fully funded by, the U.S. Department of Defense.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top